Here is the complete receptor-annotated detailed breakdown of all 13 systems:
Increased Sympathetic Activity: Effects on the Body
Overall mechanism: Postganglionic sympathetic fibers release norepinephrine (NE) onto target organs. The adrenal medulla releases epinephrine (Epi, 80%) + NE (20%) into blood. These act on α1, α2, β1, β2, β3 adrenergic receptors. α receptors prefer NE; β receptors prefer Epi.
"Stimulation of the β1-receptor causes positive inotropic and chronotropic effects on the heart, increased renin secretion in the kidney, and lipolysis in adipocytes, as well as bronchodilation and vasodilation in skeletal muscle. The α1 subtype mediates vascular and smooth muscle contraction causing vasoconstriction and increased blood pressure."
1. Piloerection
Brief: Sympathetic stimulation causes hair to stand up ("goosebumps").
Receptor: α1-adrenergic
Mechanism:
- Postganglionic sympathetic fibers innervate the arrector pili muscle (smooth muscle attached to hair follicle)
- NE binds α1 receptors → Gq protein → PLC activation → IP3 + DAG → ↑intracellular Ca²⁺ → smooth muscle contraction
- Contraction pulls the hair follicle upright → piloerection
- In animals: traps air for warmth and makes animal appear larger (threat display)
- In humans: vestigial reflex, produces goosebumps (cutis anserina)
Fiber type: Postganglionic sympathetic, unmyelinated (C fibers), via gray rami → skin branches
2. Respiration - Lungs (Bronchial Effects)
Brief: Sympathetic activity causes bronchodilation and reduces secretions.
Receptor: β2-adrenergic (dominant on bronchial smooth muscle) + α1 (on bronchial vessels)
Mechanism:
- Epinephrine (from adrenal medulla) and NE bind β2 receptors on bronchial smooth muscle
- β2 → Gs → ↑cAMP → PKA activation → phosphorylates myosin light chain kinase (MLCK) → inactivates it → smooth muscle relaxation → bronchodilation
- Simultaneously, PKA also opens K⁺ channels → hyperpolarization → further relaxation
- Bronchial glands: α1 stimulation → ↓mucus secretion (reduced secretions)
- Pulmonary vasculature: α1 → mild vasoconstriction (diverts blood to better-ventilated areas)
- Net result: ↑airway caliber → ↓airway resistance → ↑airflow to meet increased O2 demand during fight-or-flight
Clinical use: β2 agonists (salbutamol/albuterol) mimic this for asthma treatment
3. Cardiovascular System (General)
Brief: ↑heart rate, ↑contractility, ↑blood pressure, peripheral vasoconstriction.
Receptors: β1 (heart), α1 (vessels), β2 (some vascular beds)
| Effect | Receptor | Mechanism |
|---|
| ↑Heart rate (chronotropy) | β1 | ↑cAMP → PKA → ↑If (funny current) in SA node → faster spontaneous depolarization |
| ↑Contractility (inotropy) | β1 | ↑cAMP → PKA → phosphorylates L-type Ca²⁺ channels + troponin I → ↑Ca²⁺ influx + faster relaxation |
| ↑Conduction velocity | β1 | ↑cAMP in AV node → faster conduction |
| Vasoconstriction (skin, gut, kidney) | α1 | Gq → PLC → ↑Ca²⁺ → MLCK → smooth muscle contraction |
| Vasodilation (skeletal muscle) | β2 | Gs → ↑cAMP → smooth muscle relaxation |
| ↑Blood pressure | α1 + β1 | ↑peripheral resistance + ↑cardiac output |
4. Renal Blood Flow
Brief: Sympathetic activation decreases renal blood flow via vasoconstriction.
Receptors: α1 (afferent arteriole, predominant) + β1 (juxtaglomerular cells)
Mechanism:
- NE → α1 on afferent arterioles → vasoconstriction → ↓glomerular capillary pressure → ↓GFR and ↓renal blood flow
- Simultaneously, NE → β1 on juxtaglomerular (JG) cells → ↑cAMP → ↑renin release → activates RAAS → AngII → further vasoconstriction + aldosterone → Na⁺/water retention → ↑blood pressure
- α1 also acts on efferent arteriole but less potently than afferent
- Net result: ↓renal perfusion (blood diverted to heart, muscles, brain) + ↑renin → longer-term BP support
- Severe sympathetic activation (e.g., shock) can cause acute tubular necrosis from ischemia
Note: Dopamine (DA1 receptors on renal vasculature) causes vasodilation - used therapeutically in renal protection.
5. Skeletal Muscle Blood Flow
Brief: Sympathetic activity causes vasodilation in skeletal muscle (via epinephrine/β2), but vasoconstriction via NE/α1 at rest.
Receptors: β2 (metabolic vasodilation, Epi-mediated) + α1 (NE-mediated vasoconstriction at rest)
Mechanism:
- At rest: NE dominates → α1 → mild vasoconstriction (vascular tone maintenance)
- During fight-or-flight: adrenal Epi floods blood → β2 receptors on skeletal muscle arterioles → Gs → ↑cAMP → vasodilation → ↑blood flow to muscles
- Cholinergic sympathetic fibers (unique to skeletal muscle) also release ACh → muscarinic → vasodilation (anticipatory, before exercise begins)
- Local metabolic factors (↑CO2, ↓O2, adenosine) also override sympathetic tone during active exercise
- Net: ↑blood flow to contracting muscle, ↑O2 delivery, ↑glucose delivery
6. Coronary Blood Flow
Brief: Net effect = vasodilation (despite some α1-mediated constriction), primarily driven by metabolic demand.
Receptors: β2 (vasodilation) + α1 (vasoconstriction) + DA1 (dopaminergic vasodilation)
Mechanism:
- Coronary vessels have both α1 and β2 receptors
- Direct sympathetic NE → α1 → mild coronary vasoconstriction
- BUT: ↑heart rate + ↑contractility (β1 effects) → ↑myocardial O2 consumption → local metabolic vasodilators (adenosine, CO2, H⁺, K⁺) released → dominant vasodilation overrides α1 constriction
- Epi via β2 also contributes directly to vasodilation
- DA1 receptors on coronary vasculature: dopamine → vasodilation (exploited in cardiogenic shock treatment)
- Net: coronary blood flow increases during sympathetic activation to meet increased cardiac demand
7. Cerebral Effects
Brief: Cerebral circulation is relatively protected from sympathetic vasoconstriction; autoregulation dominates.
Receptors: α1 (present but weak effect) + β2 (present)
Mechanism:
- Cerebral arterioles do have α1 adrenergic receptors but they are far less responsive than peripheral vessels
- Cerebral autoregulation strongly overrides sympathetic tone - maintains constant blood flow across MAP 60-150 mmHg
- Systemic ↑BP (from sympathetic activation) may slightly reduce cerebral perfusion via myogenic response
- CNS arousal effects: sympathetic activation → release of NE from locus coeruleus → ↑alertness, attention, arousal
- ↑Glucose availability to brain (via hepatic glycogenolysis)
- Blood-brain barrier limits access of circulating catecholamines
- In severe hypertension (e.g., pheochromocytoma crisis): autoregulation fails → hypertensive encephalopathy
8. Heart - SA Node (Specifically)
Brief: Sympathetic activation increases the firing rate of the SA node → tachycardia.
Receptor: β1-adrenergic (primary) + β2 (minor)
Detailed Mechanism at SA Node:
- NE/Epi binds β1 receptor on SA nodal cells
- β1 → Gs protein → ↑adenylyl cyclase → ↑cAMP
- ↑cAMP → directly binds and opens HCN channels (If, "funny current") - these carry inward Na⁺ current during diastolic depolarization
- Faster If current → more rapid spontaneous diastolic depolarization (phase 4)
- ↑cAMP also → PKA → phosphorylates L-type Ca²⁺ channels (ICaL) → ↑Ca²⁺ entry → faster upstroke (phase 0) and lower threshold
- PKA also phosphorylates ryanodine receptors (RyR2) in SR → ↑Ca²⁺ sparks → further acceleration
- Result: shorter cycle length → ↑heart rate (positive chronotropy)
Other cardiac effects via β1:
- AV node: ↑conduction velocity (positive dromotropy)
- Ventricular muscle: ↑contractility (positive inotropy) via ↑Ca²⁺ influx
- ↑Relaxation rate (positive lusitropy) via PKA phosphorylation of phospholamban → ↑SERCA pump activity
9. Gastrointestinal Tract (GIT)
Brief: Sympathetic activation inhibits GIT activity - reduces motility, secretions; contracts sphincters.
Receptors: α1, α2 (dominant inhibitory) + β2 (smooth muscle relaxation)
| Effect | Receptor | Mechanism |
|---|
| ↓Motility (peristalsis) | α2 (presynaptic) | NE → α2 on myenteric plexus neurons → ↓ACh release → ↓peristalsis |
| ↓Motility (direct) | β2 | ↑cAMP → smooth muscle relaxation → ↓gut movement |
| ↑Sphincter tone | α1 | ↑Ca²⁺ → smooth muscle contraction → closed sphincters (esophageal, pyloric, ileocecal, internal anal) |
| ↓Secretions | α2 | ↓cAMP in secretory cells → ↓gastric acid, ↓intestinal secretions |
| ↓Splanchnic blood flow | α1 | Vasoconstriction → blood diverted to muscles/heart |
Net result: GIT is effectively "shut down" during fight-or-flight. Blood is diverted away. Digestion pauses.
10. Urinary Bladder
Brief: Sympathetic activation promotes urine retention - relaxes detrusor, contracts internal sphincter.
Receptors: β2/β3 (detrusor muscle) + α1 (internal urethral sphincter + bladder neck)
Mechanism:
- Detrusor muscle (bladder wall): NE/Epi → β2 and β3 → Gs → ↑cAMP → smooth muscle relaxation → bladder fills, does not contract → urine retained
- Internal urethral sphincter (bladder neck): NE → α1 → Gq → ↑Ca²⁺ → smooth muscle contraction → sphincter closes → urine cannot escape
- Trigone and base: α1 → contraction reinforces sphincter closure
- Net: bladder capacity ↑, micturition inhibited - logical during fight-or-flight (you don't urinate when fleeing)
- Clinical relevance: α1 blockers (tamsulosin, prazosin) relax the internal sphincter → used in BPH to aid urination. β3 agonists (mirabegron) relax detrusor → used in overactive bladder.
11. Liver Cells (Hepatocytes)
Brief: Sympathetic activation triggers glycogenolysis and gluconeogenesis in the liver → ↑blood glucose.
Receptors: α1 (dominant in liver) + β2 (minor)
Mechanism:
- NE/Epi → α1 on hepatocytes → Gq → PLC → ↑IP3 → ↑Ca²⁺ from ER + ↑DAG → PKC activation
- ↑Ca²⁺ → activates phosphorylase kinase → activates glycogen phosphorylase → breaks down glycogen → glucose-1-phosphate → glucose released into blood
- Epi → β2 (minor contribution) → Gs → ↑cAMP → PKA → also activates glycogen phosphorylase and inhibits glycogen synthase
- ↑Gluconeogenesis: PKA → ↑expression of PEPCK and other gluconeogenic enzymes
- Net: rapid ↑blood glucose to fuel muscles and brain during stress
Summary of signaling: NE → α1 → IP3/Ca²⁺/PKC → glycogenolysis; Epi → β2 → cAMP/PKA → glycogenolysis + gluconeogenesis
12. Insulin (Pancreatic β-Cells)
Brief: Sympathetic activation inhibits insulin secretion and promotes glucagon secretion.
Receptors: α2 (inhibitory, dominant on β-cells) + β2 (stimulatory, minor)
Mechanism:
- NE → α2 receptors on pancreatic β-cells → Gi protein → ↓adenylyl cyclase → ↓cAMP → ↓PKA activity → ↓exocytosis of insulin granules → ↓insulin secretion
- α2 also → opens K⁺ channels → hyperpolarization → prevents Ca²⁺ entry → further ↓insulin release
- Glucagon (α-cells): β2 → Gs → ↑cAMP → ↑glucagon secretion (counteracts hypoglycemia)
- Net metabolic effect: ↓insulin + ↑glucagon → ↑blood glucose (from liver) + ↑lipolysis (from fat)
- This ensures glucose stays available for brain and muscles during emergency
Clinical relevance: Non-selective β-blockers (propranolol) block β2 on β-cells → can mask hypoglycemia and impair recovery from low blood sugar (dangerous in diabetics).
13. Na⁺/K⁺-ATPase (Sodium-Potassium Pump) in Cells
Brief: Sympathetic activation (especially via β2) stimulates Na⁺/K⁺-ATPase → drives K⁺ into cells → can cause hypokalemia.
Receptor: β2-adrenergic
Mechanism:
- Epi/NE → β2 receptors on cell membranes → Gs → ↑cAMP → PKA activation
- PKA phosphorylates the Na⁺/K⁺-ATPase α-subunit → ↑pump activity
- Pump moves 3 Na⁺ out and 2 K⁺ in per cycle → net K⁺ uptake into cells
- This occurs in skeletal muscle, liver, heart cells
- Result: serum K⁺ falls (hypokalemia) - transient but significant
- Also occurs via β2 → ↑insulin release (minor) which also stimulates Na⁺/K⁺-ATPase
Physiological purpose:
- Maintains high intracellular K⁺ (needed for resting membrane potential)
- During exercise/stress, K⁺ leaks out of contracting muscles; β2-driven pump activity counteracts excessive hyperkalemia
Clinical relevance:
- Stress-induced hypokalemia (e.g., post-MI surge in catecholamines → ↓K⁺ → arrhythmias)
- β2 agonists (salbutamol) used to treat hyperkalemia by driving K⁺ into cells
- Non-selective β-blockers can blunt this pump stimulation → relative K⁺ retention
Master Summary Table
| System | Receptor | NE/Epi | Effect |
|---|
| Piloerection | α1 | NE | Arrector pili contracts → hair erect |
| Lungs (bronchi) | β2 | Epi | Bronchodilation, ↓secretions |
| Cardiovascular | β1 (heart), α1 (vessels) | NE+Epi | ↑HR, ↑BP, ↑contractility, vasoconstriction |
| Renal blood flow | α1 + β1 | NE | ↓RBF, ↑renin, ↓GFR |
| Skeletal muscle BF | β2 (Epi) / α1 (NE) | Epi dominant | Vasodilation (Epi) |
| Coronary BF | β2 + metabolic | Epi | Net vasodilation (metabolic demand wins) |
| Cerebral | Autoregulation dominant | - | Minimal direct effect; ↑arousal |
| SA node (heart) | β1 | NE+Epi | ↑If → ↑HR (tachycardia) |
| GIT | α2 (presynaptic), β2, α1 | NE | ↓Motility, ↑sphincter tone, ↓secretions |
| Urinary bladder | β2/β3 (detrusor), α1 (sphincter) | NE | Detrusor relaxes, sphincter contracts → retention |
| Liver | α1 (dominant), β2 | NE+Epi | Glycogenolysis → ↑blood glucose |
| Insulin (β-cells) | α2 (inhibitory) | NE | ↓Insulin, ↑glucagon |
| Na⁺/K⁺-ATPase | β2 | Epi | ↑Pump activity → K⁺ into cells → hypokalemia |
Sources: Goldman-Cecil Medicine; Medical Physiology (Boron & Boulpaep); Goodman & Gilman's Pharmacology; Neuroanatomy through Clinical Cases (Blumenfeld)